← Issue №19/ week of Nov 8, 2026/ the whole section, in full

Colorectal, in full.

All 10 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 10, in full

most clinically useful first · the 2 the issue led with are ruled in green
Colorectal rct · n=82 · Nov 6, 2026 · Am J Gastro · IF 9.8

3% Sucralfate-Containing Topical Formulation Versus 0.2% Topical Nitroglycerin for Chronic Anal Fissure: A Double-Blind Randomized Controlled Trial.

New evidencebasic sciencetranslationalepidemiology
Clinical takeawayConsider topical 3% sucralfate as an alternative to nitroglycerin for chronic anal fissure, applied twice daily, given its superior healing rates in this study.
What it foundTopical 3% sucralfate achieved 50% fissure healing at 2 weeks vs 23% with nitroglycerin (RR 2.22, 95% CI 1.16-4.26), and 79% vs 48% at 4 weeks (RR 1.65, 95% CI 1.15-2.38).
ContextThis study suggests sucralfate may be more effective than nitroglycerin for chronic anal fissure healing, but further evidence is needed to confirm its role in clinical practice.
Emergingsuggested applicable standard· American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473

… Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. … The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose anorectal abscess and fistula-in-ano clinically: a disease-specific history and physical examination assessing symptoms, relevant history, abscess and fistula location, and secondary cellulitis (1C), with digital rectal exam and anoscopy/proctoscopy as needed. Routine diagnostic imaging is NOT typically necessary (1B); reserve imaging for selected patients with occult abscess, recurrent or complex fistula, immunosuppression, or anorectal Crohn's disease (MRI sensitivity 97% vs 74% for endoanal ultrasound in complex fistula; combined accuracy approaches 100%). Treat acute anorectal abscess promptly with incision and drainage (1C), placing the incision close to the anal verge to limit subsequent tract length and preserve the sphincter complex; packing is not required and unpacked wounds gave better resolution, less pain and faster healing in randomized trials. Reserve antibiotics for abscess complicated by cellulitis, systemic signs of infection, or underlying immunosuppression (2B); routine antibiotics after uncomplicated drainage in healthy patients do not improve healing or reduce recurrence, and conversely immunosuppressed patients with low neutrophil counts and no fluctuance may initially be treated with antibiotics alone rather than drainage. Concomitant fistulotomy at the time of drainage may be performed in selected patients with a simple anal fistula (2B), balancing lower recurrence (RR 0.13 in a 479-patient meta-analysis) against a non-significant increase in continence disturbance. For simple fistula-in-ano with normal sphincter function, lay-open fistulotomy heals over 90% (1B); for low fistulas involving less than one third of the external sphincter the clinically significant incontinence risk is minimal, and marsupialization improves healing and reduces bleeding. Sphincter-preserving options: endorectal advancement flap (1B; 66% to 87% initial healing, but up to 35% mild-to-moderate incontinence) and, for transsphincteric tracts, ligation of the intersphincteric fistula tract (LIFT) (1B; 76% pooled success, 1.4% incontinence). A cutting seton may be used selectively for complex cryptoglandular fistula (2C, downgraded from 2B; reported incontinence ranges 0% to 67%). The anal fistula plug and fibrin glue are relatively ineffective (1B, upgraded from 2B; contemporary healing 50% or less). Endoscopic or laser closure techniques (VAAFT, FiLaC, OTSC) have reasonable short-term healing but unknown long-term healing and recurrence rates (2C). In Crohn's disease, where abscess and fistula arise from penetrating inflammation rather than cryptoglandular infection, management is multidisciplinary and a draining seton is typically useful and may be used for long-term disease control (1B, upgraded from 1C); Crohn's disease is a named risk factor for failure or recurrence of fistulotomy, advancement flap, LIFT, and plug.

American Society of Colon and Rectal Surgeons (ASCRS), "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula" (Gaertner WB, Burgess PL, Davids JS, et al.), Diseases of the Colon & Rectum 2022;65(8):964-985, doi:10.1097/DCR.0000000000002473 · reviewed 2026-07-19 ↗
Lohsiriwat V … Ovartchaiyapong P · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal meta analysis · n=1,763 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Risk of Distant Metastasis and Oncologic Outcomes of Clinical Near-Complete Responders After Neoadjuvant Therapy in Rectal Cancer: A Meta-Analysis.

New evidencerectal cancermeta-analysis
Clinical takeawayWeigh the higher metastasis and regrowth risk when offering watch-and-wait to near-complete responders; this analysis compares response groups and does not test whether surgery improves outcomes.
What it foundNear-complete response after neoadjuvant therapy for rectal cancer is associated with higher risk of distant metastasis (16.8% vs 7.3%; RR 2.31) and local regrowth (32.8% vs 19.7%; RR 1.75) compared to complete clinical response.
ContextTen studies, 1,763 patients; definitions of near-complete response and reassessment timing varied.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Marcolin P … Messaris E · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal prospective cohort · n=9,523 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Differences in Presentation and Prognosis of Early versus Late Diagnosis of Locoregional Recurrences after Colon Cancer Resection: A Nationwide Cohort Study.

New evidencecolorectal cancerepidemiology
Clinical takeawayNo clinical action recommended; further research is needed to determine if intensified surveillance improves outcomes for early locoregional recurrence.
What it foundLate diagnosis of locoregional recurrence (≥1 year) was associated with longer overall survival (median 18.0 vs 9.1 months; HR 0.83, 95% CI 0.69-0.99) and higher rates of curative intent treatment (34.6% vs 24.0%, p=0.01) compared to early diagnosis (<1 year). In patients treated with curative intent, overall survival did not differ between early and late locoregional recurrence (median 40.1 vs 40.7 months; HR 1.05, 95% CI 0.73-1.51, p=0.79).
ContextConfirms prior evidence that early recurrence (<1 year) is associated with poorer outcomes in palliative treatment, but refines understanding by showing survival is similar in curative-intent treatment regardless of timing.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Rademaker E … collaborators of the Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal prospective cohort · n=111 · Nov 3, 2026 · Aliment Pharm Ther · IF 6.7

Development of a Clinical and Biomarker-Based Score to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea.

Diagnosticbiomarker
Clinical takeawayNo clinical action yet: the score comes from a 111-patient derivation cohort with bootstrap internal validation, and colonoscopy with stepwise biopsies is the only method of confirming microscopic colitis.
What it foundA clinical and biomarker-based score (stool frequency >5/day, diarrhoea duration ≤8 months, BMI ≤26 kg/m2, faecal calprotectin >81 μg/g) predicted microscopic colitis with AUC 0.90 (optimism-corrected AUC 0.88) and no false negatives at the sensitivity-driven cut-off, outperforming previously published scores (Cotter, Kane, Atieh; AUCs 0.63-0.72).
ContextOutperformed the Cotter, Kane and Atieh scores in this cohort (AUC 0.63 to 0.72).
Emergingsuggested applicable standard· United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8

Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose microscopic colitis on colonoscopy with biopsies from at least two colonic segments (proximal/ascending and distal/descending, ~3 biopsies per segment in separate jars, avoiding rectum-only sampling since it can miss >20% of cases), plus celiac serology (tTG-IgA) and an infectious workup before treatment. First step is withdrawal of implicated drugs (PPIs, NSAIDs, SSRIs, and other suspected culprits such as statins/ARBs), but only for agents with a suspected chronological (temporal) relationship between drug introduction and onset of diarrhea, and only when discontinuation is clinically safe and an appropriate alternative exists, rather than reflexive class-wide withdrawal (the European UEG/EMCG guideline suggests considering withdrawal of any drug with such a temporal relationship, and notes PPI-switch data contradict a strict class effect), together with smoking-cessation counseling. For symptomatic disease, AGA's guideline recommends budesonide 9 mg once daily for 6-8 weeks as induction, preferred over mesalamine (budesonide gave nearly double the remission rate in head-to-head RCTs); when budesonide is not feasible AGA suggests mesalamine, bismuth subsalicylate, or prednisone/prednisolone as second-line alternatives, the European UEG/EMCG guideline is stricter and recommends against mesalamine outright (not superior to placebo in trials). Maintenance uses budesonide tapered to the lowest effective dose (typically 4.5-6 mg/day) individualized to the patient, since roughly 80% relapse after stopping. Budesonide non-/partial responders should be evaluated for bile acid diarrhea (cholestyramine trial can reduce budesonide dependence), celiac disease, and SIBO before escalating refractory disease to thiopurines (azathioprine/6-MP) or biologics (anti-TNF, vedolizumab).

United European Gastroenterology (UEG) & European Microscopic Colitis Group (EMCG), "European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations" (Miehlke et al.), 2021, Recommendation 1.8 · reviewed 2026-07-23 ↗
Ruiz-Campos L … Fernández-Bañares F · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
Colorectal systematic review · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Long-term (≥ 5 Years) Low Anterior Resection Syndrome and Health Related Quality of Life in Rectal Cancer Patients: A Systematic Review.

New evidencecolorectal cancerrectal cancersystematic reviewhealth services
Clinical takeawayCounsel rectal cancer patients undergoing sphincter-preserving surgery on the high likelihood of persistent LARS, particularly if they receive neoadjuvant radiotherapy.
What it foundMajor low anterior resection syndrome (LARS) persists in 39.3% of rectal cancer survivors ≥5 years postoperatively, with minor LARS in 21.5%.
ContextConfirms the high prevalence of long-term LARS after sphincter-preserving rectal cancer surgery, with neoadjuvant radiotherapy identified as a consistent risk factor.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Civilka A … Dulskas A · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal retrospective · n=41 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

Patient-Reported Outcomes after Robotic Resection of Deep Endometriosis of the Bowel.

New evidencecolorectal surgery
Clinical takeawayConsider robotic resection as an option for patients with deep endometriosis involving the bowel, particularly when pain and quality of life are significant concerns.
What it foundRobotic resection of deep endometriosis involving the bowel reduced overall pain from 5.3 to 1.6 at 6 months and 2.3 at 12 months (Numeric Rating Scale, p < 0.001) compared to preoperative baseline, and decreased pain impacting work from 88% to <40%.
ContextConfirms the efficacy of minimally invasive surgery for deep endometriosis, extending evidence to robotic approaches with improved patient-reported outcomes. Limitations include low response rate (31.7% at 12 months), single tertiary center, and retrospective design.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Addison P … Behm K · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal prospective cohort · n=71 · Nov 4, 2026 · Dis Colon Rectum · IF 3.5

Rethinking Low Anterior Resection Syndrome: Higher Than Expected Pre-Surgical Incidence and the Role of Gut Microbes.

New evidencemicrobiomecolorectal cancercolorectal surgery
Clinical takeawayAssess pretreatment bowel dysfunction in rectal cancer patients using the low anterior resection syndrome score (score ≥ 21) to guide counseling on postoperative quality of life. No clinical action based on microbial findings is currently supported.
What it found42% of rectal cancer patients had pretreatment bowel dysfunction meeting low anterior resection syndrome criteria (score ≥ 21), increasing to 64% postoperatively. Baseline microbial profiles differed between groups, but no association between bacterial diversity and low anterior resection syndrome development was found.
ContextChallenges the assumption that low anterior resection syndrome is solely a postoperative complication, highlighting its high pretreatment prevalence. However, microbial diversity does not predict low anterior resection syndrome development.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Bar-Yoseph H … Ghuman A · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal retrospective · n=320 · Nov 3, 2026 · Dis Colon Rectum · IF 3.5

A Matter of Time: Does Early vs Late Failure Impact Redo Pouch Survival?

New evidencecolorectal surgeryepidemiologyartificial intelligence
Clinical takeawayCounsel patients with late index pouch failure (>6 months post-IPAA) on their higher risk of redo pouch failure (22.8% vs 10.7% in early failure).
What it foundLate index pouch failure (>6 months post-IPAA) tripled redo pouch failure risk (HR 3.09; 95% CI 1.07-8.87) compared to early failure (≤6 months).
ContextRefines prior evidence on pouch failure predictors by showing timing of index failure is a key prognostic factor for redo pouch outcomes.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Jimenez DC … Holubar SD · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal review · Nov 2, 2026 · Nat Rev Gastro Hep · IF 57.5

The genomic and epigenomic evolution of colorectal cancer.

Basic sciencebasic sciencetranslationalbiomarkercolorectal cancer
Clinical takeawayNo clinical action yet: a mechanistic review of genomic and epigenomic changes in colorectal cancer evolution.
What it foundThe review synthesizes genomic and epigenomic changes driving colorectal cancer evolution, from transformation to metastasis and treatment resistance.
ContextRefines understanding of colorectal cancer progression by integrating genetic, epigenetic, and immune changes, aligning with current knowledge of multistep carcinogenesis.
Measured against the standard of care· USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001

Decision at stakeunderstanding the molecular drivers of colorectal cancer evolution

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). A nonpedunculated lesion with deep-invasion features should be biopsied and tattooed, then referred for surgical resection. The AGA 2025 commentary adds that endoscopic local excision, including endoscopic full-thickness resection for selected T1 lesions under 2 cm, can be considered where technically feasible. A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. ESD is often preferred to EMR because it achieves higher en bloc rates. Piecemeal resection of a suspected cancer is discouraged: it compromises histologic staging and independently predicts recurrence, and NCCN treats a T1 cancer removed piecemeal as needing surgery. After complete endoscopic removal of a malignant polyp, whether to recommend surgery depends on polyp shape, whether en bloc resection and an adequate histologic assessment were achieved, unfavorable histologic features (lymph node metastasis risk), surgical risk, and patient preference. The AGA 2025 commentary advises referral to a high-volume center with endoscopic resection and pathology expertise when the diagnosis is unclear and suspicion for cancer is high. It also advises expert GI pathology review and multidisciplinary discussion of resected T1 specimens. Lesions resected en bloc with no unfavorable histology can be managed with endoscopic surveillance instead of surgery.

USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001 · reviewed 2026-10-11 ↗
Sng CCT … Sottoriva A · Nature Reviews Gastroenterology & Hepatology · IF 57.5 · PubMed ↗Permalink
Colorectal n/a · n=3,503 · Nov 4, 2026 · Dis Colon Rectum · IF 3.5

Machine Learning-Based Risk Scoring Using Clinical and Surgical Variables for Severe Complications after Rectal Cancer Surgery.

New evidenceartificial intelligencecolorectal cancercolorectal surgerybiomarker
Clinical takeawayNo clinical action yet: a predictive model validated only internally at a single center. External validation is needed before clinical use.
What it foundMachine learning models predicted severe postoperative complications (Clavien-Dindo ≥ 3) after rectal cancer surgery with AUROC 0.898-0.910 and sensitivity 0.685-0.707, using predictors including tumor perforation, intraoperative transfusion, protective stoma, bowel obstruction, and cerebrovascular accident.
ContextDemonstrates potential to improve individualized risk prediction by integrating complex clinical and surgical variables, though validation was limited to a single center with a small prospective cohort.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Song SH … Choi GS · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Back to issue №19 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS